What Impact will GLP-1 Agonists have on Chronic Wounds?
This blog was originally posted on SmartTrak's website on March 5, 2024: https://blog.smarttrak.com/what-impact-will-glp-1-agonists-have-on-chronic-wounds. Reposted with permission.
SmartTRAK estimates that there were 77.7MM chronic wounds worldwide (US, Europe, Japan, Australia, Canada, Brazil, China and India) in 2022, of which 41.4MM were hard-to-heal. Wound numbers are forecast to grow at a five-year CAGR of +0.8%, which is higher than the forecasted population growth of +0.3% but below the growth of those aged over 65 years old.
In this article, SmartTRAK provides an overview of GLP-1 agonists, explores the possible impact these drugs will have on the conditions that drive wound prevalence and advises on how the outcomes will influence future estimates.
Among the topics covered in this article are:
- What are GLP-1 Agonists?
GLP-1 agonists are a class of drugs mimicking the action of a hormone called glucagon-like peptide 1. The drugs stimulate glucose-dependent insulin release from the pancreas. A range of agonists have been developed and launched, with the first product being ... (read more)
- What is the Future for GLP-1 Agonists?
Financial indicators suggest that GLP-1 agonists are expected to expand significantly in use around the world. The two companies with drugs licensed for weight loss have seen record share price growth are ... (read more)
- What Impact Are GLP-1 Agonists Expected to Have on Diabetes and Obesity?
When GLP-1 agonists were launched in 2005, they required twice daily injections. This was driven by the rapid elimination, or short half-life, of the compounds. With further development, companies have improved usability and weekly injections and ... (read more)
- How will GLP-1 Agonists Impact SmartTRAK Forecast for Wound Prevalence?
SmartTRAK estimates wound numbers by type for the most recent full year and forecasts five years into the future. These estimates and forecasts are ... (read more)
In recent years, there has been a significant increase in published research into the weight-loss effect of GLP-1 agonists in both diabetic and non-diabetic patients. A 2023 systematic review with meta-analysis showed that GLP-1 agonists significantly reduced body weight (11.7lb mean difference), body mass index (2.4kg/m2) and waist circumference (1.7 inches) in non-diabetic obese or overweight patients. To read more, please click here.
SmartTRAK is the Medtech industry’s only global Insights-as-a-Service solution for the Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapy markets. SmartTRAK’s propriety methodology turns disparate data from hundreds of sources into powerful insights customers can rely on as the trusted source for strategic decision-making. The SmartTRAK enterprise platform includes rich daily updates, comprehensive market coverage and simple-to-use tools and dashboards for market, product and financial analysis. Customers leveraging the SmartTRAK platform also have direct access to market experts for inquiries and advisory services. If you would like a demo of what SmartTRAK has to offer and see how we can help increase proficiency, improve productivity and reduce costs for your company, just click here.
